Scienture Holdings, Inc. 8-K

What Happened
Scienture Holdings, Inc. (SCNX) announced it entered into and closed a note purchase agreement with Streeterville Capital, LLC on April 27, 2026, issuing two secured promissory notes. The Company issued a Secured Promissory Note A-1 (original principal $8.42 million, $400,000 original issue discount) and a Secured Promissory Note B ($3.0 million). At closing the lender paid $8.0 million to the Company and deposited $3.0 million into a deposit account at Lakeside Bank for the Company’s newly formed subsidiary (SCNX Holdings, LLC) subject to a Deposit Account Control Agreement. Maxim Group LLC served as placement agent. The Company said it will use proceeds for working capital, commercialization expenses, portfolio/product development, and general corporate purposes.

Key Details

• Closing date: April 27, 2026. Total stated principal: $11.42M (A-1 $8.42M with $400k OID; B $3.0M). Net cash to company at close: $8.0M plus $3.0M held in controlled deposit account. Company paid $20,000 of lender transaction costs.
• Interest & term: A-1 interest 9% per annum; B interest 5% per annum. Both notes mature 18 months after issuance. Prepayment allowed but subject to a 115% premium if refinancing is by a third party.
• Redemption & conversion features: Beginning 8 months after closing, lender may redeem up to $175,000 per month and may effect a limited redemption tied to stock trading price/volume. Company may exchange portions of the B Note into new A-1-form notes each time A-1 outstanding is reduced by $1M (Section 3(a)(9)).
• Security, covenants & default mechanics: Obligations are secured by the deposit account control agreement, guaranty from subsidiaries, security agreements (including IP), and a pledge of SCNX Sub membership interests. Notes include Major and Minor trigger events that can (after notice/cure periods) increase outstanding balances by 15%/5% per occurrence (up to 25% aggregate), accelerate repayment, and raise interest to up to 18% upon default.

Why It Matters

• Liquidity and use of proceeds: The transaction provides near-term cash (direct payment and controlled deposit) to fund working capital, commercialization and development—important for operations and product advancement.
• Financial and operational constraints: The financing is secured and contains covenants (e.g., maintaining SEC reporting and exchange listing, restrictions on subsidiary activities) and significant default/penalty mechanics that could materially increase the Company’s obligations if specified events occur.
• Investor considerations: The notes carry higher interest and strict remedies on defaults (including potential sizeable balance increases and rapid acceleration). Retail investors should note the collateralization and covenants when assessing company risk and capital structure; full agreement texts are filed as exhibits to the 8-K for detailed review.